SCM
TVTX icon

Semanteon Capital Management’s Travere Therapeutics TVTX Stock Holding History

Semanteon Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15,006
Closed -$269K – 269
2025
Q1 		$269K Sell
15,006
-69,777
-82% -$1.42M 0.15% 204
2024
Q4 		$1.48M Buy
84,783
+48,084
+131% +$850K 0.79% 9
2024
Q3 		$513K Buy
+36,699
New +$382K 0.35% 127

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Semanteon Capital Management's TVTX Position: Q2 2025 in Review

Semanteon Capital Management sold out of Travere Therapeutics (TVTX) in Q2 2025, closing a stake of 15,006 shares — an estimated $269K sold.

Semanteon Capital Management first reported a position in TVTX in Q3 2024 and held it in 3 quarters. The position peaked at $1.48M in Q4 2024. 211 funds tracked by Wall St. Rank hold TVTX as of Q2 2025.

  • Semanteon Capital Management reported no remaining Travere Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Semanteon Capital Management sold 15,006 Travere Therapeutics shares in Q2 2025, an estimated $269K.
  • Semanteon Capital Management first reported a position in Travere Therapeutics in Q3 2024 and held it in 3 quarters.
  • Semanteon Capital Management's Travere Therapeutics position peaked at $1.48M in Q4 2024.
  • 211 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2025.

Based on Semanteon Capital Management's 13F filing for Q2 2025, filed 11 Aug 2025.